The Biopharmaceutical Classification System (BCS) divides drugs into one of four classes according to their solubility and permeability. Solid dispersion can be defined as a dispersion of one or more active ingredients in an inert carrier or matrix in the solid state prepared by the melt, solvent or solvent-melt method. In the current research Indomethacin solid dispersions are prepared and evaluated for better solubility and bioavailability.

Antihypertensive suffer from the disadvantages of extensive first pass metabolism and variable bioavailability, so they were considered ideal Patch candidate. Atenolol, a β-adrenergic receptor antagonist, has been shown to be safe and effective in the treatment of patients with hypertension. It has a mean plasma half-life of 6 hrs and only 45% of the orally administered drug reaches the circulation due to hepatic metabolism. A model reported predicts that mean plasma Atenolol concentration of 43, 99 and 175 ng/ml are required to produce a 20%, 30%, and 40% reduction in blood pressure respectively. The aim of present investigation is to formulate and optimize the Atenolol matrix diffusion controlled rectal drug delivery system. In the present investigation, the influence of various grades and concentration of polymers were studied. Study was carried out to formulate an elegant product exhibiting desired therapeutic performance, from a small and cute dosage form.In order to achieve this goal, following criteria were set; the dosage form should remain intact for a period of 24hr.Drug is delivered in a controlled manner.The size of dosage form should be small with a view to enhance convenience of patient as well as compliance to therapy.Plasma concentration should achieve within short period of time.

The decreasing number of approved drugs produced by the pharmaceutical industry, which has been accompanied by increasing expenses for R and D, demands alternative approaches to increase pharmaceutical R and D productivity. This situation has contributed to a revival of interest in peptides as potential drug candidates. New synthetic strategies for limiting metabolism and alternative routes of administration have emerged in recent years and resulted in a large number of peptide-based drugs that are now being marketed. This review reports on the unexpected and considers able number of peptides that are currently available as drugs and the chemical strategies that were used to bring them into the market. As demonstrated here, peptidebased drug discovery could be a serious option for addressing new therapeutic challenges.